Ranexa
Product indicated to support angina pectoris management and designed to relieve symptoms by modifying cardiac ionic currents.
Strengths: 500 · 1000mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Anti-anginal Drug
- Pharmacological class
Late Sodium Current Inhibitor
- Minor side effects
dizziness; constipation; nausea; headache
- Moderate side effects
fatigue; asthenia; blurred vision
- Dosage forms
Prolonged-release tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Menarini
- Onset Time
1–2 days
- Duration
24 hours
- Drug interactions
ketoconazole; verapamil; diltiazem; simvastatin
- Age restrictions
Not recommended for those under 18 years.
- Pregnancy and breastfeeding
Pregnancy: Not recommended. Breastfeeding: Not recommended.
Contraindications
hypersensitivity; severe renal impairment; severe hepatic impairment; concurrent use of potent CYP3A4 inhibitors
Precautions and warnings
monitor for arrhythmias; use caution in elderly patients; regular electrocardiogram monitoring required
Serious side effects
qt prolongation — requires immediate medical attention; ventricular arrhythmias — requires immediate medical attention; syncope — requires immediate medical attention
Patient summary
Product indicated to support angina pectoris management and designed to relieve symptoms by modifying cardiac ionic currents.
Mechanism of action
This medicine inhibits the late sodium current in heart muscle cells, which prevents sodium and calcium overload, improving cardiac relaxation and blood flow efficiency.
Storage instructions
Store at room temperature, keep in original packaging, and protect from moisture.
Ranexa
Product indicated to support angina pectoris management and designed to relieve symptoms by modifying cardiac ionic currents.
Editorial Notes
- Active ingredient(s): Ranolazine
- Listed indication(s): Stable Angina Pectoris
Usually available as
- 60 tablets - 500 mg1060-500-mg-15568
- 30 tablets - 1000 mg1060-1000-mg-15572